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Available online 27 July 2013Abstract The outcomes of clinical trials using bonemarrow stromal cell (BMSC) are variable; the degree of the expansion of BMSCs
during clinical manufacturing may contribute to this variability since cell expansion is limited by senescence. Human BMSCs from
aspirates of healthy subjects were subcultured serially until cell growth stopped. Phenotype and functional measurements of BMSCs
from two subjects including senescence-associated beta-galactosidase staining and colony formation efficiency changed from an
early to a senescence pattern at passage 6 or 7. Transcriptome analysis of 10 early and 15 late passage BMSC samples from 5 subjects
revealed 2122 differentially expressed genes, which were associated with immune response, development, and cell proliferation
pathways. Analysis of 57 serial BMSC samples from 7 donors revealed that the change from an early to senescent profile was variable
among subjects and occurred prior to changes in phenotypes. BMSC age expressed as a percentage of maximum population doublings
(PDs) was a good indicator for an early or senescence transcription signature but thismeasure of BMSC life span can only be calculated
after expanding BMSCs to senescence. In order to find amore useful surrogatemeasure of BMSC age, we used a computational biology
approach to identify a set of genes whose expression at each passage would predict elapsed age of BMSCs. A total of 155 genes were
highly correlated with BMSC age. A least angle regression algorithm identified a set of 24 BMSC age-predictive genes. In conclusion,
the onset of senescence-associated molecular changes was variable and preceded changes in other indicators of BMSC quality and
senescence. The 24 BMSC age predictive genes will be useful in assessing the quality of clinical BMSC products.
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Bone marrow stromal cells (BMSCs) which are also known as
mesenchymal stromal cells (MSCs) were first described by
Friedenstein et al. (1966). They have anti-inflammatory and
immunosuppressive properties and are being tested in a large
number of clinical trials for many different applications
(Ciccocioppo et al., 2011; Dash et al., 2009; Hare et al., 2009;
Joyce et al., 2010; Karussis et al., 2010; Le Blanc et al., 2004;
Mazzini et al., 2010; Pal et al., 2009; Saleem et al., 2000). In
most cases a relatively small number of BMSCs are isolated from
bone marrow aspirates or bone biopsies by plastic adherence
and expanded by serial passage. The typical cell dose is 1 to
2 × 106 cells per kg of recipient weight or 75 to 200 × 106 cells.
The production of those doses of BMSCs from 10 to 15 mL of
aspirated marrow requires the expansion of BMSCs over 3 to
4 weeks. The expansion capability of BMSCs, however, is
limited. Prolonged BMSC culture leads to deterioration of
their replication ability and eventually to senescence (Ksiazek,
2009; Wagner et al., 2010). Those changes are associated with
morphological changes, a reduction in proliferation ability, the
loss of the ability to differentiate into bone, cartilage and
adipose tissue (Banfi et al., 2000; Digirolamo et al., 1999; Sethe
et al., 2006; Tanabe et al., 2008) and the down-regulation of
stemness-related and DNA repair genes (Galderisi et al., 2009).
Indiscriminate use of senescent BMSCs in clinical trials may lead
to negative results and compromise the entire nascent field of
BMSC therapy.
We investigated the effects of serial expansion on BMSCs
isolated from marrow aspirates. BMSCs were analyzed for
morphology, colony formation efficiency (CFE), immunophe-
notype, senescence associated beta-galactosidase (SA β-gal)
staining and global gene expression profiles.
We identified a BMSC transcription signature that was
associated with senescence and found that the onset of the
change from an early passage to a senescence transcription
signature was variable among donors and preceded senescence-
associated changes in phenotype and function. BMSC age,
expressed as the percentage of life span completed and
calculated using population doublings (PDs), was a good
marker for an early or senescence transcription profile.
Although this measure of BMSC age is valuable, the calcula-
tions can only be made retrospectively after expanding BMSCs
to senescence. In order to find a surrogate measure of BMSC
age, we used a computational biology approach to identify a
set of genes whose expression at each passage would predict
elapsed age of BMSCs. A least angle regression (LAR) method
which uses a linear regression model to predict a continuous
response was used to identify the least number of genes whose
expression predicts BMSC age. We identified a set of 24
age-predictive genes, which will be useful in determining
whether clinical lots of BMSCs have begun to show signs of
senescence or not.
Material and methods
Serial culture of BMSCs
Marrow collection and BMSC culture were performed according
to a Standard Operating Procedure (SOP) established in our lab
(Sabatino et al., 2012). After obtaining informed consent,marrowwas collected from the posterior iliac crest of 7 healthy
donors. A total of 5 to 10 mL of marrow was collected in Bone
Marrow Prep Syringes (Pharmacy Department, NIH, Bethesda,
MD) and then washed with 2.5× volume of HBSS (Lonza,
Walkersville, MD); no density gradient centrifuge was per-
formed. A single cell suspension was made with BMSC culture
media (BMSC CM) [alpha MEM with 2 mM glutamine (Lonza),
supplemented with 20% lot-selected FBS (Hyclone, Thermo
Fisher Scientific, Waltham, MA) and 10 μg/mL Gentamicin] and
plated at a density of 2 × 105/cm2 in T-75 flasks (Corning Life
Sciences, Corning, NY) and were incubated at 37 °C in 5% CO2.
Non-adherent cells were removed after 24 h; the media was
changed every three days until the colonies reach 70–80%
confluence when the primary BMSCs were harvested. The
primary BMSCs were washed with 10 mL HBSS twice and lifted
with 5 mL TrypLE Express (Invitrogen, Life Technologies, Grand
Island, NY), the cells were then centrifuged at 406 ×g for
10 min and the cell number was counted and viability was
assessed by Trypan Blue exclusion method. The cells harvested
at this stage were designated as passage 1, and serial passage
numbers were designated thereafter. After passage 1, the
BMSCs were seeded on plastic surface at a density of
3000 cells per cm2, cultured and harvested when they reach
70–80% confluence.
Passage 4 BMSCs were banked as clinical products and the
lot release criteria were (1) ≥70% viability, as determined
by Trypan Blue exclusion method, (2) No bacteria growth
after 14 days of inoculation, as determined by Bactec Plus,
aerobic and anaerobic, (3) Negative for mycoplasma, as
determined by PCR, (4) b5 EU/mL Endotoxin, as measured
by the Limulus Amebocyte Lysate (LAL) assay, (5) ≥80% of
the cells express CD105, CD73 and CD90, and ≥60% of the
cells express CD146, as measured by flow cytometry, and (6)
≤5% of the cells express CD45, CD14, CD34, and CD11b. In
addition, we set up in process controls during the production
process; (1) at primary culture stage, multiple BMSC colonies
must be visible and the confluence must be ≥70% on the day
of harvest; and (2) at the expansion stage, the confluence
should be ≥70% and the viability ≥70% on the day of
harvest.
The number of BMSCs at every passage was manually
counted and the PD for each passage was calculated using
equation:
N ¼ log2 NH=N1ð Þ
where N = population doublings, NH = cell harvest number,
and NI = plating cell number.
Cumulative PDs were calculated in relation to the number of
cells at the first passage. Population doubling time (PDT) was
calculated for each passage. These studies were approved by an
NHLBI committee on the use of human subjects in research.
Flow cytometry analysis
BMSC surface markers were analyzed by flow cytometry. The
cells were stained with: CD73 (CD73-PE, BD Bioscience, San
Diego, CA), CD105 (CD105-APC, eBioscience, San Diego, CA),
CD146 (CD146-PE, BD Bioscience), CD44 (CD44-APC, BD
Bioscience), and isotype control. Data were collected on a
FACSCalibur (BD Bioscience) and analyzed using FlowJo
software (Tree Star, Inc., Ashland, OR).
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3 × 104 BMSCs were fixed with 4.5 mL of ice-cold 70% ethanol
for one hour and then washed thoroughly with phosphate
buffered saline (PBS). The fixed BMSCs were incubated with
0.5 mL Propidium Iodide/Triton-x-100/RNase A (all from Sigma
Aldrich, St. Louis, MO) at room temperature for 30 min. Data
were collected on the FACSCalibur and analyzed using FlowJo
software.
SA β-gal staining
BMSCs were stained using a Senescence Associated Beta-Gal
Staining kit (Sigma Aldrich) following the manufacturer's
protocol. Briefly, BMSCs were washed with PBS, fixed with
Fixation Buffer for 7 min at room temperature, washed with
PBS, and then incubated with staining mixture at 37 °C
overnight. The senescent cells under 10 randomly selected
high-magnitude microscope fields (100×) were counted on
the following day.
CFE enumeration
BMSCs were plated at 10/cm2 in 6-well plates and cultured for
13 days without changing culture medium. The colonies were
then fixed with methanol for 30 min and stained with
saturated methyl-violet water solution for 20 min. Colonies
were observed under low magnitude light microscope field
(25×). Colonies, initiated by the colony-forming units—
fibroblasts (CFU-Fs) and containing 50 or more cells of
fibroblastic morphology were counted, and colony-forming
efficiency (CFE; number of BMSC colonies/plating BMSCs)
was calculated.
Mixed lymphocyte reaction inhibition
The immunosuppressive properties of BMSCs were compared
using Mixed Lymphocyte Reaction (MLR) assay (SAIC-Frederic,
Frederic, MD). Ficoll-separated peripheral blood mononu-
clear cells (PBMCs) were plated in 96-well plates at 1 × 105
responders per well. Responders were co-cultured with
2500 cGy irradiated stimulator PBMC at a concentration of
1 × 105 cells/well. BMSCs at passages 3, 6 and 9 were added
at the following concentrations: 104, 4 × 104 and 105 cells/
well. Culture plates were incubated for 6 days in a humidified
5% CO2 incubator at 37 °C. On the day of harvest, 0.5 μCi of
3H-thymidine (3H-TdR) was added to each well for 4 h with
lymphocyte proliferation measured using a liquid scintillation
counter. The effect of BMSCs on MLR was calculated as the
percentage of the suppression comparedwith the proliferative
response of the positive control without BMSC, where the
positive control was set to 0% suppression. The experiments
were performed three times for each variable described.
Cytokine and growth factor analysis of BMSC culture
supernatant
The cytokine and growth factor concentrations in BMSC
culture supernatant were evaluated using SearchLight
Protein Array Analysis (Aushon BioSystems, Billerica, MA).Culture supernatant was collected, centrifuged for 10 min at
1400 rpm to remove cell debris and then stored at −80 °C.
The supernatants of BMSC from donors 09FC20 (passages 3, 6,
9) and W10003 (passages 3, 6, 9, 11) were evaluated for
CXCL12 (SDF1), IL-6, IL-8, IL-10, TGFB1, SPP1 (osteopontin,
OPN), ICAM1, TNFRSF11B (osteoprotegerin, OPG), BDNF, CSF1
(M-CSF), LIF, HGF, VEGF, CCL22 (MDC), SAA1, PTGS2 (COX-2)
and TNFSF10 (TRAIL).Microarray gene expression analysis
Total RNA was extracted using miRNeasy Mini Kit (Qiagen,
Hilden, Germany) and assessed using Nano Drop 2000 (Thermo
Scientific,Wilmington, DE). Microarray expression experiments
were performed on 4 × 44 K Whole Human Genome Microarray
(Agilent Technologies, Santa Clara, CA, USA) according to our
protocols (Wang et al., 2012). Generally, 0.5 μg of BMSC RNA
was labeled with Cyanine 5-CTP, and Universal Human
Reference RNA (Stratagene, Santa Clara, CA, USA) was labeled
with Cyanine3-CTP using a Quick Amp Labeling kit (Agilent),
which uses T7 RNA polymerase to simultaneously amplifies
target material and incorporates Cy 3 or Cy 5-labeled CTP into
complimentary RNA (cRNA). After purification, 825 ng of
labeled cRNA from BMSC and reference RNA was pooled,
fragmented and then hybridized on 4 × 44K microarrays for
17 h at 65 °C. Images of the arrays were acquired using a
microarray scanner G2505B (Agilent Technologies) and image
analysis was performed using feature extraction software
version 9.5 (Agilent Technologies). The Agilent GE2-v5_95
protocol was applied using default settings. The data were
submitted to Gene Expression Omnibus (GEO) under accession
number GSE34303.Data processing and statistical analyses
Global gene expression analysis was performed according to
a standard procedure (Wang et al., 2012). Raw data was
uploaded into mAdb database (http://madb.nci.nih.gov/)
and then imported into BRB-ArrayTools (Simon et al., 2007)
(http://linus.nci.nih.gov/BRB-ArrayTools.html). Tests for
differences between early, and late stages were conducted
for individual genes using two-sided t tests, considering P
values of b0.001 as significant, with adjustment for the
donor effect. The Benjamini and Hochberg method was used
to estimate the false discovery rate. The same tests were
also used to identify the differentially expressed genes
among early, middle and late passage BMSCs, considering P
values of b0.0001 as significant, with adjustment for the
donor effect. The Pearson correlation coefficients were used
to identify genes that were highly correlated with the BMSC
age. Least Angle Regression (LAR) method was used to
develop a linear model for predicting the life span (BMSC
age) based on gene expression measurements (Efron et al.,
2004). The error of the prediction model was estimated
using a leave-one-donor-out cross validated approach (Zhao
and Simon, 2010). Clusters and Heatmaps were generated
using MultiExperiment Viewer (MeV4.6.2, http://www.tm4.
org/mev/) (Saeed et al., 2003). Pathway analysis was based
on GeneGo database (www.genego.com) and Ingenuity
Pathway Analysis Database (www.ingenuity.com).
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available datasets
To assess the efficacy of our BMSC “age” prediction model, we
analyzed datasets that were deposited in Gene Expression
Omnibus (GEO), in which microarray analysis was performed
on MSCs that were cultured to replicative senescence using
Affymetrix Human Genome U133 Plus 2.0 array (GSE7888
and GSE9593). The microarray data was imported into BRB
ArrayTools and filtered to show the 24 predictive genes.
One gene FLJ00254 protein was not found on the platform
Affymetrix Human Genome U133 plus 2.0 array and its
annotation has been discontinued, so it was excluded from
analysis. For those genes that had multiple probes, only the
probe has the highest intensity was selected for further
analysis. After that, the percentage of the maximum
lifespan of each sample was calculated using the formula
∑ icixi + 0.143 where ci and xi are the coefficient and gene
expression for the i-th gene, respectively. The gene expres-
sion here is log-intensity for single-channel data.Results
BMSC growth
BMSCs used in this study were isolated and expanded from
marrow aspirates collected from 7 consenting donors. The
BMSCs were subcultured serially until replicative senes-
cence. Growth kinetic analysis showed a rapid increase in
proliferation in passage 2 and passage 3 cells, followed by a
phase of slow growth and finally no proliferation. Growth
began to slow after 5 to 7 passages and stopped after 8 to 12
passages (Fig. 1a). The BMSCs underwent a total of 25 to 40
population doublings (PDs) (Fig. 1a). Population Doubling
Time (PDT) at each passage varied among individual donors,
but steadily increased with passage number (Fig. 1b). The
mean PDTs from passage 2 to passage 9 were 34.8 ± 6.5 h or
hours (passage 2), 37.4 ± 13.7 h (passage 3), 38.5 ± 11.3 h
(passage 4), 36.7 ± 10.2 h (passage 5), 39.0 ± 9.6 h (passage
6), 46.9 ± 13.3 h (passage 7), 69.9 ± 44.1 h (passage 8) and
162.7 ± 194.9 h (passage 9). BMSCs from 6 donors reached
passage 10 with a mean PDT of 80.5 ± 18.8 h. BMSCs from 3
donors reached passage 11 with a mean PDT of 101.1 ±
48.5 h. Only one donor reached passages 12 and 13 and the
PDTs were 113.10 h and 331.52 h respectively. BMSC mor-
phology changed from thin and spindle-shaped among early
passage cells (Fig. 1c) to large, flattened, and irregularly
shaped among late passage cells (Fig. 1d).Kinetics of phenotype changes associated with
BMSCs senescence
To identify the onset of phenotype and functional changes
associated with prolonged BMSC expansion, BMSCs from 2
donors (09FC20 and W10003) were thawed from a working
cell bank and serially passaged until senescence. They were
assessed for CFE, cell cycle, SA β-gal staining, cell surface
markers, immunosuppressive effects and supernatant
growth factors/cytokine levels.In general, CFE was high initially (15–20%) and increased
with passages until it reached a peak of 25–35% at passages 3
through 7 and then gradually fell until it reached 0 or 1 colony
with less than 50 cells at senescence (Figs. 1e, f). SA β-Gal
assay revealed that the number of senescent BMSCs was low
and stable for early passages, passages 2 through 7 for 09FC20
and 2 through 6 for donor W10003. The number increased
abruptly over the 2 following passages and increased more
gradually over the later passages (Figs. 1g, h).
The percentage of CD73 and CD105-positive cells remained
stable, while the percentage of CD146-postive cells decreased
in late passage cells. The percentage of CD44-positive cells
increased slightly in late passage 09FC20 cells, but decreased
in late passage W10003 cells (Fig. 2a). The mean fluorescence
intensity (MFI) of the BMSC surface markers CD73, CD105,
CD146 and CD44 on donor 09FC20 cells increased with passage
despite a higher isotype background at passage 9; while the
MFI of these 4 surface markers decreased with passage of
donor W10003 cells (Fig. 2b).
Cell cycle analysis revealed that the proportion of cells in
S phase increased from passage 2 or 3 to passage 5 and then
decreased. The proportion of cells in G2 and S phases fell at
passages 7, 8, and 9 and increased markedly at passage 10
(Figs. 2c and d). This finding was not surprising since an
increased number of cells with 4C DNA content, probably G1
tetraploid cells, have been observed in premature senes-
cence (Pitto et al., 2009).
We hypothesized that the immunosuppressive effects of
BMSCs will be deteriorated by long-term culture and therefore
examined the influence of BMSC expansion on their inhibition
to lymphocyte proliferation using a mixed lymphocyte reac
tion (MLR) assay. As expected, BMSCs at passage 9 were
markedly less suppressive than those at passages 3 and 6;
while no significant differences were observed between
passage 3 and passage 6 (Figs. 2e and f).
Cytokine/chemokine secretion was another key phenotype
associated with senescence of BMSC. For example, X-ray
irradiation induced the up-regulation of GRO, IL-8, IL-12 and
MDC (CCL22) in human MSC supernatant (Wang and Jang,
2009); a modified secretory senescence (mSS) signature
comprised of IL6, IL8, TGFB1, etc, revealed increasing
senescence with passage of MSCs (Lafferty-Whyte et al.,
2010). We measured the concentrations of proteins whose
genes were differentially expressed between early and
late passage BMSCs (P b 0.001), including CXCL12, VEGF,
TNFSF10 (down-regulated in late passage cells), and IL-6,
IL-8, TNFRSF11b, BDNF (up-regulated in late passage cells).
Some genes whose expression changed with passages but
with less statistical significance (P N 0.001) were also
measured. These genes included SPP1, CSF1, LIF, CCL22
and SAA1, which we think may be involved in the
senescence of BMSCs, and TGFB1, HGF, and PTGS2 which
are associated with the immune-modulatory functions of
BMSCs. Among the proteins analyzed, only 4 were detected
in culture medium, TGFB1 was of high level, while BDNF,
CXCL12 and VEGF were at low levels. In the BMSC
supernatant, IL-10, TNFSF10 and PTGS2 were too low to be
detected. The concentrations of IL-6, IL-8, ICAM1 and
TNFRSF11B were much higher in passage 9 supernatants
than passage 3 and 6 supernatants (Table 1 and Supplemen-
tary Material S1). The concentration of CSF1 and SPP1
increased drastically over passages and reached peak
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levels of CXCL12, SAA1 and TGFB1 decreased greatly with
passages; HGF and LIF were generally decreased but with
donor variance; the other proteins BDNF and VEGF did not
undergo significant change through the culture (Table 1 and
Supplementary Material S1).
Comparison of early and late passage BMSCs from 5
donors by global gene expression analysis
The CFE, PDT, cell cycle, and SA-β-gal analysis suggested
that BMSCs are relatively stable for 6 or 7 passage. To further
assess the nature of changes associated with senescence at a
molecular level, we performed global transcriptome analysis
on early and late passage BMSCs from 5 donors: 09FC37,
09FC43, 09FC44, 09FC45 and 09FC49. The early passage cells
were from passages 2 and 3 and the late passage cells were
from the three passages immediately prior to senescence.
Unsupervised hierarchical clustering separated the samples
into two clusters, one with all 10 early passage samples and
one with all 15 late passage samples, passages 6 through 12
(Supplementary Material S2). We then identified 2122Figure 1 Growth kinetics, morphology, CFE and senescence of BM
Each line represents BMSCs from one donor and each symbol represe
added up to get the cumulative PD. (b): The mean Population Doublin
of BMSC at early passage. (d) Morphology of BMSC at late passage. Th
donor W10003 (f), data were normalized by the number of plating BM
(g) and W10003 (h) at each passage were shown. Passage (P) was indifferentially expressed genes between the two groups (2
sample t-test with blocking of donor effects, P-value b 0.001,
fold change N 1.5). Among these genes, 922 were
up-regulated and 1200 down-regulated by early passage
BMSCs compared to late passage cells (SupplementaryMaterial
S2). Ingenuity Pathway Analysis showed that genes
up-regulated in early passage BMSCs were overrepresented in
immune response pathways, development associated path-
ways, while the genes up-regulated in late passage BMSCs
were over-represented in cell proliferation pathways, immune
response pathways (Supplementary Material S2).
Kinetics of molecular changes defined by global
gene expression analysis of 7 donors
Analysis of the early and late passage BMSCs from 5 donors
revealed marked transcriptional differences but did not
provide precise information as to the onset of the molecular
changes associated with senescence; we therefore analyzed
57 BMSC samples from all 7 donors to clarify these changes.
For further analysis we calculated BMSC “age” rather than
passage number using a published method (Stenderup et al.,SCs. (a): The Cumulative Population Doublings (PD) for 7 donors.
nts one passage. Population doublings (PD) of each passage were
g Time (PDT) of multiple donors at each passage. (c) Morphology
e CFE assay was performed on BMSCs from donor 09FC20 (e) and
SCs. The numbers of SA β-gal positive cells of BMSCs from 09FC20
dicated below x-axis.
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percentage of the maximal life span, i.e. the population
doubling (PD) at each passage was divided by the total number
of PDs at senescence. The BMSC samples at each passage were
then classified as early, middle and late stages based on their
age. Passages whose accumulative PDs were less than 50% of
maximum life span were considered early stage; those with
50% to 80% of maximum life span weremiddle stage; and those
with accumulative PDs greater than 80% of maximum life span
were late stage (Stenderup et al., 2003). Principal component
analysis (PCA) using genes the expression of which in more
than 20% of the BMSC samples was higher or lower than the
median value by greater than 1.5-fold separated the samples
into 3 groups; BMSCs at early stage were located primarily
within a single group, BMSCs at late stage were primarily
within another group, while BMSCs at middle stage were
located in a group between them (Fig. 3a). The early stageFigure 2 Surface marker, cell cycle phase and functional changes
expressing surface markers CD73, CD105, CD146 and CD44 from donor
of surface markers for BMSCs from donor 09FC20 and W10003. (c):
Results of cell cycle analysis on BMSCs from donor W10003, passage
x-axis. (e): The immunosuppressive effects of BMSCs from donor 09
W10003. Number of BMSCs per well was indicated below the bars. E
between passages 3, 6 and 9 were determined by two sample t-testgroup included BMSCs at passages 2 through 5, and late stage
group included BMSCs from passages 8 through 11 (Fig. 3a).
Interestingly, the BMSCs in middle stage group, representing a
transition from early to late stage and with passage numbers
ranging from 5 to 9, were quite heterogeneously distributed.
For instance, the passage 9 BMSCs from donor 09FC37 and
passage 7 cells of donor 09FC20 were close to early stage
group, while passage 4 cells of donor 09FC49, passage 5 cells of
donors 09FC44 and 09FC45 were close to late stage samples.
These results revealed that there was variability among donors
in the onset of molecular changes associated with senescence
and, in general, the onset of molecule changes associatedwith
senescence preceded the onset of phenotype and function
changes.
For further analysis, we identified 1067 differentially
expressed genes among early, middle and late stage BMSCs
(group comparison analysis with donor effect blocked, and Passociates with BMSC expansion. (a): The percentage of BMSCs
09FC20 and W10003. (b): The mean fluorescence intensity (MFI)
Results of cell cycle analysis on BMSCs from donor 09FC20. (d):
(P), and cell cycle phage G1, S, and G2 were indicated below
FC20. (f): The immunosuppressive effects of BMSCs from donor
rror bars indicated standard deviation. Statistical significances
, and P values were indicated above the bars.
1066 J. Ren et al.value b 0.0001 as significant). Mixed effects ANOVA models
were also performed using stage as the fixed factor and
donor as the random factor. With the mixed effects models,
1070 genes were found to be differentially expressed
(P b 0.0001) among stages, which is comparable to 1067
differentially expressed genes identified in class comparison
among stages when blocking the donor effect. Hierarchical
clustering analysis using the 1067 differentially expressed
genes revealed that BMSCs were segmented into two major
clusters (Fig. 3b); the first cluster contained all of the early
stage samples plus most of the middle stage samples; while
the second cluster included all late stage samples and the
remaining middle stage samples (Fig. 3b). The middle age
sample signature appeared to represent a transition from the
early stage to the late stage. The early stage samples included
passage 2 through 5 samples, but passage 4 and 5 sampleswere
also present in the middle stage samples. These results show
that BMSC age expressed as percentage of the maximal life
span provides a good indication on whether BMSCs will have an
early or late age molecular profile.
Those results showed that the expression of BMSC age as a
percent of maximum life span is a useful marker of early and
senescent BMSC transcription signatures. Unfortunately, it
can only be calculated by growing the cells to senescence, a
condition that is non-applicable to clinical manufacturing.
Therefore we searched for genes whose expression could be
used to predict BMSC age prospectively.Identification of a set of BMSC age-predictive genes
Because of the relatively early onset of molecular changes
associated with senescence in some donors, it would be
worthwhile to identify markers that could be used to evaluate
final clinical BMSC products and ensure they retain an early
gene expression signature.
First, we calculated the Pearson correlation coefficients
of each individual gene with the percentage of maximum life
span, which stood for the BMSC age. This analysis identifiedTable 1 The concentrations (pg/mL) of proteins in the supernat
Factors Culture medium Donor 09FC20
Passage 3 Passage 6 Pas
IL-6 – 16,421.68 10,920.21 51,5
IL-8 – 630.94 480.49 67
BDNF 25.0 308.76 902.57 9
ICAM1 – 148.47 152.88 6
CSF1 – 203.45 144.15 3
TNFRSF11B – 47.25 275.99 12
SPP1 – 364.49 594.17 40
CXCL12 52.5 22,712.19 18,464.34 12,2
TGFB1 17,025.5 40,134.34 36,949.30 35,7
SAA1 – 26,882.40 19,814.58 18,4
VEGF 3.2 16,161.31 13,102.05 22,7
LIF – 309.13 256.36 3
HGF – 2692.63 5756.90 37
CCL22 – 6.82 6.21
–: not detected.155 genes whose expression levels were highly correlated
with the BMSC age (correlation efficient ≥ 0.7) (Supple-
mentary Material S3). Then, we investigated the onset of the
transition from an early to late life span signature for each of
the 7 subjects using hierarchical clustering analysis using the
155 “age”-correlated genes. Hierarchical clustering sepa-
rated the BMSC samples from each donor into two groups; an
earlier gene expression signature group and a later signature
group (Fig. 3c). For each of the 7 subjects all early stage
BMSCs were in the earlier signature cluster and all late stage
BMSCs were in the later signature cluster. Most of the middle
stage BMSCs were clustered with late stage BMSCs, with
single samples from only 2 donors clustering with early stage
cells and samples from 1 donor clustering with both early
and late signature groups. Specifically, earlier stage BMSCs
included passages 2 and 3 for 09FC45 and 09FC49, passages
2, 3, and 4 for W10003, and passage 5 and less for 09FC20,
09FC37 and 09FC43, and 09FC44. However, some samples in
the transition area, passages 6 and 7, were not available for
09FC37, 09FC43, and 09FC44; therefore the conclusions that
can be made from these donors are somewhat limited. These
results also show that the transition from an early to a late
transcription signature is variable among donors.
GeneGo Process Network analysis of these 155 genes
revealed that genes up-regulated at earlier passages were
overrepresented by Notch Signaling, Wnt Signaling, TGF-β,
GDF and Activin Signaling; and Development of Ossification
and Bone Remodeling (Table 2); while genes up-regulated at
late passages were overrepresented by Chromatin Modifica-
tion; Blood Vessel Morphogenesis; Cell Cycle and IL-10 Anti-
inflammatory Response (Table 2). Among these pathways,Wnt
Signaling pathway is instrumental for the bone development; 3
genes, TGFB3, MAP2K6, andWISP1 were up-regulated by early
passage BMSCs; Wnt-induced secreted protein 1 (WISP1) is a
modulator of BMSC proliferation and osteogenic differentia-
tion (Inkson et al., 2008), overexpression of WISP1 enhanced
both in vitro osteogenic differentiation and osteogenesis in
vivo (Ono et al., 2011); it can also alleviate the biglycan
(BGN)-inhibited proliferation of BMSC (Inkson et al., 2009).ant of BMSCs.
Donor W1003
sage 9 Passage 3 Passage 6 Passage 9 Passage 11
74.52 23,184.07 24,462.14 40,656.32 34,727.54
14.29 177.19 126.83 1207.35 4082.80
35.42 346.28 552.37 468.25 413.18
48.72 167.21 198.35 307.91 491.05
86.05 86.22 63.82 75.28 172.32
07.68 20.92 334.63 465.08 572.84
02.43 2819.78 1047.16 2197.46 3637.69
44.89 12,798.60 5418.17 3207.16 698.46
84.64 29,086.97 19,178.13 20,957.20 17,920.62
79.18 18,063.59 11,348.43 8784.44 9103.86
62.92 12,757.75 5277.18 5839.16 6687.93
05.97 206.38 130.52 123.24 64.02
44.90 42,658.13 15,782.62 9651.02 801.24
4.56 6.41 2.93 2.65 2.46
1067Intra-subject variability in human bone marrow stromal cell replicative senescenceWe then built a linear model for predicting a continuous
response variable based on gene expression profile using Least
Angle Regression/LASSO algorithm (Efron et al, 2004). This
method avoids the over-fitting characteristic of least-squares
linear regression when the number of variables (i.e., genes) is
large compared to the number of cases (i.e., donors). In order
to get an unbiased estimate of the true prediction error, we
included leave-one-donor-out cross validation to estimate the
squared prediction error for each model. In each round, the
data of one donor was omitted. A linear model was built based
on remaining data in a stepwise manner. The prediction error
was recorded for the datawithheld. This process was repeated
for each donor. The model with the minimum estimated
squared prediction error was selected as the final model.
Fig. 4a shows the scatter plot of the cross validated predicted
response values versus the actual values, which indicated that
the R square, a measure of the predicted life span vs. the
actual life span, was 0.91.
The prediction model identified a data set with 24 genes
which were able to predict the life span of each BMSC
sample at different passages. The names of the 24 genes andFigure 3 Clustering of BMSCs from 7 donors. (a): Principal Compon
passage cells (blue spheres), middle passage (green spheres) and late
1067 differentially expressed genes separated the 57 BMSC samples
shown by blue font, middle stage by green and late stages by red.
separated the individual samples from each donor into an earlier sign
font stands for early stage, green for middle stage and red for latethe prediction model were shown in Table 3, and the
expression of the 24 genes was described in Supplementary
Spreadsheet S4. Hierarchical clustering analysis using the 24
predictive genes separated the 57 BMSC samples into one
cluster of 25 earlier passage BMSC samples and one with
32 later passage BMSCs (Fig. 4b). The later passage group
contained two sub-clusters, one with 12 intermediate passage
cells, passages 5 through 8, and a late passage group, passages
7 through 12 (Fig. 4c).Assessment of clinical BMSCs' quality using the age-
predictive gene set
To determine if the 24 age-predictive genes might be useful for
evaluating clinical BMSC products, we assessed 12 BMSC lots
produced in our clinical processing laboratory using good
manufacturing practices (Sabatino et al., 2012). All lots were
isolated frommarrow aspirates of healthy donors and expanded
by 4 serial passages. Unsupervised hierarchical clustering using
4895 genes with a standard deviation greater than 0.4ent Analysis (PCA) separated the BMSCs into three clusters, early
passage (red spheres). (b): Hierarchical clustering analysis using
into two clusters. P stands for Passage, early stage cells were
(C): Hierarchical clustering using the 155 age-correlated genes
ature group and later signature group, P stands for Passage, blue
stage.
Table 2 GeneGo process network analysis of the 155 age-correlated genes.
Early passage up-regulated
genes
Late passage up-regulated genes
Networks P-value Genes P-value Genes
Signal transduction NOTCH signaling 1.00E−04 HEYL, TGFB3,
MAP2K6, LFNG
2.25E−02 CCND1, FZD4, SMURF2, CCND1
Signal transduction WNT signaling 2.64E−04 TGFB3, MAP2K6,
WISP1
1.97E−01 CCND1, FZD4
Transcription chromatin modification 3.53E−01 HIST1H4C,
HIST1H4B
2.70E−03 HDAC9, HIST2H2AA3, HIST1H2BK,
HIST1H2BE, HIST1H2BC
Development_blood vessel morphogenesis 5.42E−01 CXCL12 3.64E−03 TEK, PLAT, EDN1, ADRB2, OXTR
Development_EMT_regulation of
epithelial-to-mesenchymal transition
6.93E−03 MAP2K6, TGFB3,
DES
3.92E−03 SMURF2, FZD4, EDN1, KRT14, KRT18
Cell cycle_G0–G1 2.14E−01 CDKN2C 4.16E−03 CCND1, HDAC9
Inflammation_IL-10 anti-inflammatory
response
2.55E−01 MAP2K6 7.34E−03 CCND1, TLR4
Signal transduction_TGF-beta, GDF and activin
signaling
1.38E−02 MAP2K6, RUNX2,
TGFB3
5.09E−01 CCND1
Development_ossification and bone
remodeling
1.51E−02 MAP2K6, , RUNX2,
TGFB3
5.21E−01 FZD4
Cell adhesion_platelet–endothelium–
leucocyte interactions
2.01E−02 CD40, TGFB3 4.62E−02 PLAT, EDN1, CD36
Reproduction_FSH-beta signaling pathway 4.18E−01 MAP2K6 4.62E−02 CCND1, PSG1, PSG6
Signal transduction_BMP and GDF signaling 3.70E−02 MAP2K6, RUNX2 3.46E−01 SMURF2
Cytoskeleton_intermediate filaments 2.40E−01 DES 3.56E−02 KRT14, KRT18
1068 J. Ren et al.separated the 12 lots into two clusters: one with 8 lots
(cluster-1) and one with 4 lots (cluster-2) (Fig. 4c), and
clustering using the 24 age-predictive genes separated the
12 lots into the same two clusters (Fig. 4d). The median age
of the 8 donors in cluster-1 was 23.3 years and ranged from
21.7 to 42.5 years, while the median age of the 4 donors in
cluster-2 was 58.1 years and ranged from 21.3 to 67.9 years.
All 8 lots in cluster-1 met lot release criteria, but only one lot in
cluster-2 met lot release criteria. One of the three lots failing
tomeet lot release criteria, lotW1103 had higher CD34 positive
percentage, which exceeded our release criteria of b5%. The
other two lots W1004 andW1104, which were from the 2 oldest
donors, 67 and 59 years of age, had slow proliferation during
primary culture stage and failed to meet the standards of our
manufacturing protocol (Sabatino et al., 2012). Although lot
W1101 in cluster-2 met the lot release criteria, it was from the
third oldest donor, 57 years of age. Interestingly, the calculat-
ed percentage of maximal life span of samples in cluster-2 was
much higher than those in cluster-1 (Table 4). These results
showed that the age-predictive data set was able to identify
slower growing and likely “older” BMSCs and may be useful in
identifying poor quality BMSCs.
Validation of the prediction model using publicly
available datasets
To assess the efficacy of our BMSC “age” prediction model,
we analyzed datasets deposited in GSE7888 and GSE9593. The
expression of the predictive genes was filtered out and the
percentage of maximum lifespan was calculated using our
formula. Due to the discrepancy of the platform used (Agilent
microarrays in our study vs Affymetrix microarrays for theother studies), the calculated percentages for some samples
were off scale. However, for the BMSCs from 9 subjects
analyzed, 6 from GSE7888 and 3 from GSE9593, the calculated
percentage of maximum lifespan increased with passage.
When the cells entered the senescent stage, this percentage
was much higher than for those at early passages (Supplemen-
tary file 5 and 6). These results indicated that our prediction
model is of universal interest for evaluating the in vitro senes-
cence of BMSCs.Discussion
While BMSCs are being used clinically to treat a wide variety
of conditions, the results of these clinical trials have been
variable. This may be due in part to differences in BMSC
manufacturing methods. One variable among BMSC ma-
nufacturing methods is the number of passages used to
produce the final product. Some laboratories use 3 or 4
passages while others use 5 or 6 passages (Horwitz et al.,
2002; Koc et al., 2000, 2002; Le Blanc and Ringden, 2007; Le
Blanc et al., 2003). It is known that prolonged culture of
BMSCs is associated with the loss of proliferation potential
and likely the loss of function (Banfi et al., 2000; Tanabe et
al., 2008). We characterized changes that occurred in
BMSCs with prolonged culture and found that molecular
changes preceded phenotype and functional changes. The
marked differences in molecular signatures between early
and late passages occurred over multiple passages and the
timing of these changes varied among individuals.
Conventional measurements of senescence such as SA
β-gal staining, CFE, and PDTs suggested that BMSCs were
Figure 4 Prediction model of BMSC age (a): Scatter-plot of the actual life span vs the predicted life span of each sample (black
dots) from the leave-one-donor-out cross-validation. (b) Hierarchical clustering analysis using the 24 age-predictive genes separated
the 57 samples into one cluster of 25 earlier passage BMSCs and one with 32 later passage BMSCs, the later cluster contained one
sub-cluster with intermediate passage cells and one sub-cluster of late passages. (c): Unsupervised hierarchical clustering separated
the 12 clinical BMSC lots into two clusters: cluster-1 with 8 lots and cluster-2 with 4 lots. (d): Hierarchical clustering using the 24
age-predictive genes also separated the 12 lots into two clusters, one with 8 lots (cluster-1) and the other one with 4 lots (cluster-2).
1069Intra-subject variability in human bone marrow stromal cell replicative senescencerelatively stable for several passages before showing signs of
senescence. The proportion of cells staining with SA β-gal
was very low until passage 6 or 7. CFE levels were somewhat
variable, but did not fall below passage 2 levels until after
passage 7 or 8. PDTs remained stable until passage 7.
The results of gene expression profiling were consistent
with the results of SA β-gal staining and CFE assays in that
passage 7 and greater BMSCs showed significant signs of
senescence for all three assays. In contrast, gene expression
analysis differed from the other two assays in that it
consistently characterized only passages 2 through 5 as early
passage BMSCs. Gene expression analysis generally placed
passage 6 cells in a transition between early and late passages
and passage 7 and later were generally in the late passage
group. This suggests that the molecular changes associated
with BMSC senescence begin at passage 4 or 5, but do not result
in a senescence-associated phenotype until passage 6, 7 or
later. While all functionally important BMSC properties may
not be affected by senescence, the results of gene expression
analysis suggest that if a critical BMSC function or property
does change with cell passage, significant changes may occur
before traditional markers of senescence are apparent.When the molecular signatures of each donor's BMSC
samples were analyzed individually, we noticed that the BMSC
samples were clustered from lowest to highest passages for all
7 donors. This is consistent with the results of Schallmoser et
al., (2010) and Wagner et al. (2008), who analyzed serial
passages of BMSCs from three donors. These results suggest
that some changes in BMSCs occur with each passage;
however, the magnitudes of these changes with each passage
are minor relative to the difference between the earliest and
latest passage cells. This also provides further evidence that
the transition from an early to late passage phenotype is
gradual and all early passage cells may not have identical
functional properties.
A number of important differences in gene expression
occurred with prolonged BMSC passage. Stem cell related
genes, including Wnt and Notch signaling genes, were down-
regulated in late passage cells. In addition, genes involved
with DNA replication, recombination and repair, cell cycle,
chromatin modification and repair were up-regulated at late
cell passages. This is consistent with the association of senes-
cence with cell cycle arrest, resistance to apoptosis and
chromatin reorganization (Schallmoser et al., 2010). A number
Table 3 Prediction model of BMSC age. The predicted age
of new samples can be calculated by the expression of these
24 genes and the formula: ∑ icixi + 0.143 where ci and xi are
the coefficient and gene expression for the i-th gene,
respectively. The gene expression is the (normalized) log
ratios for dual-channel data.
UG cluster Symbol Map location Coefficient
1 Hs.559718 AK5 1p31 0.007
2 Hs.439145 SCN9A 2q24 0.007
3 Hs.535845 RUNX2 6p21 −0.003
4 Hs.124638 TMEM90B 20p11.21 −0.011
5 Hs.656071 ADAMTS9 3p14.1 −0.001
6 Hs.269764 BACH2 6q15 −0.014
7 Hs.646614 KLF8 Xp11.21 −0.001
8 Hs.244940 RDH10 8q21.11 0.038
9 Hs.483238 ARHGAP29 1p22.1 −0.026
10 Hs.1407 EDN2 1p34 0.008
11 Hs.131933 PLBD1 12p13.1 −0.068
12 Hs.369265 IRAK3 12q14.3 −0.009
13 Hs.148741 RNF144B 6p22.3 0.005
14 Hs.525093 NDFIP2 13q31.1 0.003
15 Hs.124299 FAM167A 8p23–p22 0.009
16 Hs.183114 ARHGAP28 18p11.31 0.002
17 Hs.596680 EYA4 6q23 −0.005
18 Hs.652230 TM7SF4 8q23 −0.001
19 Hs.89640 TEK 9p21 0.032
20 Hs.377894 GCA 2q24.2 −0.017
21 Hs.439145 SCN9A 2q24 0.02
22 Hs.681802 FLJ00254 protein 1 0.019
23 Hs.492974 WISP1 8q24.22 −0.001
24 Hs.122055 C7orf31 7p15.3 −0.006
Table 4 Calculated percentage of maximum life span of
clinical BMSC products.
Donor Age
(years)
Calculated
percentage
of maximum
life span
Met lot
release
criteria
Cluster
BMSC-W1002 22.9 41.47% Yes Cluster-1
BMSC-W1003 22.8 35.97% Yes Cluster-1
BMSC-W1005 21.7 33.59% Yes Cluster-1
BMSC-W1006 23.7 42.69% Yes Cluster-1
BMSC-W1007 27.2 25.40% Yes Cluster-1
BMSC-W1105 27.6 30.21% Yes Cluster-1
BMSC-W1106 22.7 35.74% Yes Cluster-1
BMSC-W1108 42.5 35.83% Yes Cluster-1
BMSC-W1004 67.9 58.56% No a Cluster-2
BMSC-W1101 56.8 47.65% Yes Cluster-2
BMSC-W1103 21.3 45.40% No b Cluster-2
BMSC-W1104 59.4 52.68% No a Cluster-2
The percentage of maximum life span was calculated based on
the prediction model described in Table 3.
a Poor proliferation during primary culture.
b High CD34+ percentage.
1070 J. Ren et al.of immune response related genes were also down-regulated
in late passage cells, suggesting that differences in anti-
inflammatory and immune modulatory properties likely exist
between early and late passage BMSCs. We found that the
suppression of BMSCs on MLRs was reduced in late passage
cells, but further functional studies are required to determine
the effects of BMSC age on specific immune modulatory or
anti-inflammatory effects.
We also characterized growth factors and cytokines in the
BMSC culture supernatant, which revealed results consistent
with a previously described senescence-associated secretory
phenotype, including rising levels of IL-6, IL-8, ICAM-1 and
TNFRSF11B (Coppe et al., 2008; Lafferty-Whyte et al., 2010;
Wang and Jang, 2009). Cytokine/chemokine secretion was
another key phenotype associated with senescence of BMSC.
For example, X-ray irradiation induced up-regulation of GRO,
IL-8, IL-12 and MDC (CCL22) in human MSC supernatant (Wang
and Jang, 2009). Senescence signaling gradually increases
with passages when analyzed using all biomarkers, but there
was a sharp increase in the senescence signaling in certain
passages, specifically, at passage 6 in Damage Associated
Senescence markers and at passage 7 in Modified Secretory
Senescence markers (Lafferty-Whyte et al., 2010). When we
calculated the percentage of maximum lifespan of BMSCs using
our prediction model and the same dataset (GSE9593), we
identified a very similar trend (Supplementary file 6). Senes-
cent human fibroblasts secrete numerous proteins, including
IL-6 and IL8, and shed cell surface molecules ICAM1 andTNFRSF11B (Coppe et al., 2008); TNFRSF11Bwas expressed to a
higher extent in senescent hMSC (Benisch et al., 2012). Some
proteins secreted by senescent cells can act in an autocrine
manner to reinforce the senescence growth arrest or promote
degenerative of hyperproliferative changes in neighboring
cells. For instance, IL-6 prevents cell cycle progression once
the senescence program is engaged (Kuilman et al., 2008) and
IL-8 reinforces senescence via CXCR2 receptor (Acosta et al.,
2008). We also observed the sharp increase of SPP1 (OPN) at
late passage BMSCs. SPP1 serves as an attachment protein
linking cells to the bone mineral and facilitates osteoclast
migration to sites of resorption. In addition to its function as a
structural protein, SPP is also involved in signaling transduc-
tion. For example, it is involved in the IL-12 and IFN-γ
responses. It increases IL-12 secretion of mouse macrophages,
but suppressed the IL-10 response and thus it represents an
essential early step in the pathway that leads to type 1
immunity (Ashkar et al., 2000). Interestingly, SPP1 was
up-regulated with the age of subjects providing the BMSCs
(Jiang et al., 2011), and these datawere in agreementwith our
data to some extent. Therefore it will be very interesting to
investigate the roles of these cytokines in human BMSC. Genes
involved in the Development of Ossification and Bone Re-
modeling were up-regulated in early passage BMSCs, which is
consistent with the reports that late-passage BMSCs exhibited
decreased bone formation capacity in both in vivo experiments
(Stenderup et al., 2003) and in vitro differentiation assays
(Siddappa et al., 2007).
Considerable variability was detected among BMSCs from
the 7 subjects. The total number of passages and accumula-
tive PDs of each donor's BMSCs was highly variable. More
important, the onset of BMSC transition from an earlier to a
later transcription profile varied among the donors. This
transition occurred after passage 5 in four donors, after
passage 4 in one donor and after passage 3 in two donors.
1071Intra-subject variability in human bone marrow stromal cell replicative senescenceBecause of this biological variability, it is important to develop
biomarkers that can be used to assess clinical BMSC lots to
determine if they show signs of changes associated with
prolonged passage at the time of final harvest. Therefore, we
searched for genes that predicted BMSC age based on the
hypothesis that most critical BMSC functions will change with
prolonged passage, and the changes in the expression of genes
reflecting BMSC age can be used as a surrogate marker for
quality control of clinical BMSCs products. However, global
gene expression analysis yields notoriously large data sets that
contain thousands of genes as potential markers and it is
essential to refine these data sets using appropriate models.
The LAR algorithm developed by Efron et al. (2004) is one such
model. It attempts to avoid the over-fitting characteristic of
least-squares linear regression when the number of variables
(genes) is large compared to the number of cases (samples).
This algorithm has been implemented into BRB-ArrayTools as a
plug-in for building a linear model for predicting a continuous
response variable based on gene expression measurements
(Zhao and Simon, 2010). Using the LAR model, we identified a
set of 24 genes predictive of BMSC age, which were as
effective as the entire gene set for identifying clinical BMSC
lots that grew slowly and likely were functionally “older” at
the time of harvest. Furthermore, the age predictive data set
recognized one BMSC lot that did not meet lot release criteria
based on CD34+ cell percentage as being different or “older”
than the BMSC lots meeting lot release criteria. That 24-gene
set included functionally important genes such as WISP1,
RUNX2, KLF8, TM7SF4, ADAMTS9, IRAK3 and EYA4 whose
expression decreased with BMSC age, while the expression of
TEK, ARHGAP29 and SCN9A was increased with age. The
expression of RUNX2, a regulator of osteoblast differentiation
(Ducy et al., 1997), has been reported to be decreased in late
passage BMSCs (Tanabe et al., 2008), but the other genes have
not previously been found to be associated with BMSC age.
WISP1 modulates BMSC proliferation and osteogenic differen-
tiation (Inkson et al., 2008), TM7SF4 plays a role in
osteoclastogenesis (Kukita et al., 2004), IRAK3 is a negative
regulator of Toll-like receptor (TLR) signaling (Kobayashi et
al., 2002), EYA4 is a transcription activator involved with the
regulation of the innate immune response (Okabe et al.,
2009), KLF8 is a transcription factor that involved with the
regulation of epithelial tomesenchymal transition (EMT) (Wang
et al., 2007), ARHGAP29 may be a tumor suppressor gene
(Ripperger et al., 2007) and TEK is a receptor for angiopoietin-1
(Oskowitz et al., 2011).
In conclusion, the onset of molecular changes associated
with BMSC passage precedes the onset of senescence-
associated changes in commonly used indicators of BMSC quality
such as SA β-gal staining, PDT and CFE. Those molecular
changes occurred over multiple passages and the timing of the
changes varied among individuals. A set of 24 age-predictive
genes may be useful in assessing the quality of clinical BMSC
products.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.07.005.
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